WATERTOWN, Mass., Oct. 13, 2025 (GLOBE NEWSWIRE) -- Remix Therapeutics (Remix), a clinical-stage biotechnology company developing small molecule therapies to modulate RNA processing and address the ...
"The preclinical data for REM-422 provide strong therapeutic rationale for our ongoing Phase I study in AML and High-Risk MDS," said Peter Smith, Ph.D., President and Chief Executive Officer of Remix ...
WATERTOWN, Mass., Oct. 24, 2025 (GLOBE NEWSWIRE) -- Remix Therapeutics (Remix), a clinical-stage biotechnology company developing small molecule therapies to modulate RNA processing and address the ...
(MENAFN- GlobeNewsWire - Nasdaq) WATERTOWN, Mass., Jan. 06, 2026 (GLOBE NEWSWIRE) -- Remix Therapeutics (Remix), a clinical-stage biotechnology company developing small molecule therapies to modulate ...
The c-MYB oncogene plays a key role in hematopoietic cell differentiation and proliferation. Genetic abnormalities and dysregulation of MYB have been found in several cancers, including adenoid cystic ...
WATERTOWN, Mass., Oct. 13, 2025 (GLOBE NEWSWIRE) -- Remix Therapeutics (Remix), a clinical-stage biotechnology company developing small molecule therapies to modulate RNA processing and address the ...
Study Evaluates Antitumor Activity and Safety of REM-422, a First/Best-in-Class Small Molecule MYB mRNA Degrader, in Patients with Adenoid Cystic Carcinoma WATERTOWN, Mass., Oct. 13, 2025 (GLOBE ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results